OAFI presents results of three scientific studies at the World Congress of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases

OAFI International Foundation has participated in the World Congress of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO) which held its nineteenth edition from 4 to 7 April in Paris. The WCO-IOF-ESCEO is one of the largest and most prestigious international scientific meetings in the field of osteoporosis, osteoarthritis, fragility and sarcopenia. OAFI Foundation presented at this Congress the result of three scientific studies, carried out with the aim of continuing to gain knowledge to improve the quality of life of patients with osteoarthritis.

Two of the initiatives presented at the WCO-IOF-ESCEO -“Results of the Global OsteoArthritis Patient Perception Survey (GOAPPS)” and “Social and individual factors that may influence the quality of life of patients with knee osteoarthritis : a Systematic Review “- are the result of an international task force (OsteoArthritis Task Force) led by OAFI International Foundation together with the Arthritis Foundation in the United States and involving members of the Pan American League of Associations for Rheumatology (PANLAR) in North and South America, and patients affiliated with the Italian Society of Rheumatology, as well as other world experts in osteoarthritis.

These two works performed with the international team have been used to compile the global perception of how OA impacts on patients’ lives. The objectives are to assess current global osteoarthritis management pathways and to improve patients’ quality of life through more efficient management and the definition of consistent evidence-based messages for the entire medical care team.

The third study presented at the WCO-IOF-ESCEO -“Expert consensus on the appropriate oral use of SYSADOA for the treatment of patients with osteoarthritis in primary care: Delphi study”- has been led by the OAFI Foundation to enable Primary Care providers to make a more correct use of these drugs.

The initial results of these studies will be disseminated at upcoming conferences and at the 3rd International Congress of Osteoarthritis Patients to be held on 3, 4 and 5 October in Barcelona.